phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer: DESTINY-Breast12.2021...
brain metastasisCNS involvementHER2‐positive breast cancerT‐DM1trastuzumabtucatinibBackground Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)﹑ositive breast cancer. Radiation and surgery are currently the main local treatment ...
[4] Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer brain metastasis: A new and exciting landscape. Cancer Rep (Hoboken). 2020 Sep 3:e1274. [5] Collins J et al. Prevalence of brain mets in HER2+ mBC increases with number of prior lines of treatment and survival ...
[5] Michelon I.F. , Vilbert MS , Marinho A.D., et al. Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis. 2023 ESMO,abs 414P. [6] Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer....
[14].Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010 Jun 1;28(16):2698-704. ...
1. Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer brain metastasis: A new and exciting landscape. Cancer Rep (Hoboken). 2020 Sep 3:e1274. 2. U.S. Department of Health and Human Services Foo...
1.Weil, R.J., et al., Breast Cancer Metastasis to the Central Nervous System. American Journal of Pathology ,2005.167(4):p.913-920. 3.Lombardi, G., et al.,Systemic treatments for brain metastases from breast cancer,non-small cell lung cancer, melanoma and renal cell carcinoma: An overv...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
et al. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology. Breast Cancer. 20...
[5]Michelon I.F,Vilbert M.S,Marinho A.D,et al.Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis:A systematic review and meta-analysis.2023 ESMO 414P. [6]Harbeck N,Modi S,Jacot W,et al.Trastuzumab Deruxtecan vs Treatment of Physician's Choice in Patients With HER2...